Ms. Harshita Dubey1, Ms. Sathya V Merla1, Dr Amar Ranjan1
1All India Institute of Medical Sciences, New Delhi, NEW DELHI, India
Biography:
Harshita is a PhD student at the premier institute in India. She is working on oncology. Her interest is in searching a novel biomarker for diagnosis of cancer.
Abstract:
Introduction
Mantle cell lymphoma (MCL) constitutes 2-10% of non-Hodgkin lymphoma. We aim to analyze secondary infections in MCL.
Method
Case study
Result
Case 1: A 55-year-old female presented with painful swelling in her neck & enlarged tonsils for 1 year. No hepatosplenomegaly or B symptom was seen. Bone marrow (BM) aspirate and biopsy showed no infiltration. PET-CT showed generalized lymphadenopathy involving supra- and infra-diaphragmatic regions. In the lungs, nodular opacities were seen in both lower lobes (8 mm size) with no FDG uptake. Lymph node biopsy showed lymphocytes positive for CD20, CD5, BCL-2, and Cyclin D and negative for CD3, CD10, BCL6, MUM1, and CD23. Ki-67 was 50%. MCL was advised. After 6 cycles of RCHOP, clinical remission was seen. PET-CT showed normal lung structures. After maintenance with Rituximab, the patient has been having a treatment-free interval for the last one & half years.
Case 2: A 68-year-old male presented with cervical lymphadenopathy. He had nodules in his eyelids for 4 years. The hemogram showed pancytopenia. Bone marrow aspirate and biopsy showed lymphoid cells positive for CD20, CD43, BCL2, & CD23 and negative for CD3, CD5, & Cyclin D1. CECT showed Waldeyer’s ring, orbital mass, & lytic lesions in iliac bones. MRI showed enlarged lacrimal glands and bulky inferior recti. Conjunctival mass-biopsy showed lymphoid cells positive for Cyclin D, CD45, & CD20, suggesting MCL. After 4# BR regimen, clinical remission was achieved. The patient remained disease-free for 3 years.
Conclusion
Lung involvement in MCL needs careful evaluation to start therapy.